116613-81-1

Basic information

• Product Name: (S)-tert-butyl (1-hydroxypent-4-en-2-yl)carbamate
• Synonyms: (S)-tert-butyl (1-hydroxypent-4-en-2-yl)carbamate;(S)-N-Boc-2-aminopent-4-en-1-ol;tert-butyl (S)-(1-hydroxypent-4-en-2-yl)carbamate
• CAS NO: 116613-81-1
• Molecular Formula: C10H19NO3
• Molecular Weight: 201.26276
• Mol File: 116613-81-1.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 323.9±35.0 °C(Predicted)
• Appearance: /
• Density: 1.011±0.06 g/cm3(Predicted)
• PKA: 11.98±0.46(Predicted)
• CAS DataBase Reference: (S)-tert-butyl (1-hydroxypent-4-en-2-yl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-tert-butyl (1-hydroxypent-4-en-2-yl)carbamate(116613-81-1)
• EPA Substance Registry System: (S)-tert-butyl (1-hydroxypent-4-en-2-yl)carbamate(116613-81-1)

Safety Data

• Hazardous Substances Data: 116613-81-1(Hazardous Substances Data)

Usage

General Description

(S)-tert-butyl (1-hydroxypent-4-en-2-yl)carbamate is a chemical compound with the formula C10H19NO3. It is a carbamate derivative with a chiral center, which means it exists in two enantiomeric forms. (S)-tert-butyl (1-hydroxypent-4-en-2-yl)carbamate is commonly used as a reagent in organic synthesis and pharmaceutical research. It is known for its ability to act as a protective group for amines and as a precursor to other functionalized compounds. The (S) configuration of this compound indicates its stereochemistry, which is important for its reactivity and biological activity. Overall, (S)-tert-butyl (1-hydroxypent-4-en-2-yl)carbamate is a versatile chemical with diverse applications in the field of organic chemistry.

Upstream product

• 151436-20-3 tert-butyl (S)-2-[(tert-butoxycarbonyl)amino]pent-4-enoate 
• 16338-48-0 L-allylglycine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 119479-32-2 2-((tert-butyloxycarbonyl)amino)-4-pentenoic acid 
• 50299-15-5 methyl (S)-allylglycinate 
• 90600-20-7 (2S)-2-[(tert-butoxycarbonyl)amino]pent-4-enoic acid 
• 118169-13-4 (S)-methyl 2-((diphenylmethylene)amino)pent-4-enoate 
• 89985-87-5 methyl (2S)-2-tert-butoxycarbonylamino-4-pentenoate 
• 335627-91-3 (4S,5R)-4-allyl-5-methoxy-2-oxazolidinone 
• 335628-27-8 (4S,5R)-4-allyl-3-tert-butoxycarbonyl-5-methoxy-2-oxazolidinone 
• 54594-06-8 D-allylglycine 
• 150652-96-3 (R)-2-(tert-butoxycarbonyl)amino-4-pentenoic acid methyl ester 
• 118169-12-3 (R)-methyl 2-((diphenylmethylene)amino)pent-4-enoate 
• 188347-88-8 (4R, 5S)-4-allyl-5-(1,2-bis(isopropoxycarbonyl)hydrazino)-2-oxazolidinone 

Downstream Products

• 1590381-75-1 (2S,3R,5R)-N-(tert-butoxycarbonyl)-3-bromo-5-nosylamino-2-phenyl-piperidine 

Relevant articles and documents

BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE

Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2, L, W1, W2, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

A west he row sandbank intermediate preparation method

The invention discloses a preparation method for a sitagliptin intermediate and belongs to the field of drug synthesis. The preparation method comprises the following steps: (1) carrying out a ring-opening reaction: carrying out Grignard reaction on 2,4,5-trifluorobromobenzene and a Grignard reagent RMgX in a medium of tetrahydrofuran and methyl tertiary-butyl ether at (-20) DEG C to 50 DEG C by taking cuprous chloride as a catalyst, wherein R2 is isopropyl and X is halogen, and then carrying out the ring-opening reaction on the generated compound and a compound shown in a formula 3 to obtain a compound shown in a formula 4; and (2) carrying out an oxidizing reaction: carrying out the oxidizing reaction on the compound shown in the formula 4 and potassium permanganate in an acetone medium, quenching and neutralizing the product by using reducing agents sodium sulfite and sodium hydrogen sulfite, and extracting the product by methyl tertiary butyl ether to obtain the sitagliptin intermediate. The method is low in cost, high in yield, mature in process and suitable for industrial production.

NOVEL QUINOLINE-SUBSTITUTED COMPOUND

An object to be achieved by the present invention is to provide a novel compound having EGFR inhibitory effects and cell growth inhibitory effects, as well as a medication useful for the prevention and/or treatment of cancer based on the EGFR inhibitory effects. The present invention provides a compound represented by Formula (I) below, or a salt thereof.